The Annals the journal of Pharmacy Technology
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 31 January 2006, www.theannals.com, DOI 10.1345/aph.1G224.
 The Annals of Pharmacotherapy: Vol. 40, No. 2, pp. 234-240. DOI 10.1345/aph.1G224
© 2006 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Joy, M. S
Right arrow Articles by Hudson, J. Q
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Joy, M. S
Right arrow Articles by Hudson, J. Q

FORMULARY FORUM

Lanthanum Carbonate

Melanie S Joy, PharmD FCCP

Associate Professor, School of Medicine, Division of Nephrology, University of North Carolina; Carolina Kidney Center, Chapel Hill, NC

Abhijit Kshirsagar, MD

Assistant Professor, School of Medicine, Division of Nephrology, University of North Carolina; Carolina Kidney Center

Corina Candiani, MD

Research Associate, School of Medicine, Division of Nephrology, University of North Carolina; Carolina Kidney Center

Tyson Brooks, PharmD

Pharmacy Practice Resident, Methodist University Hospital, Memphis, TN

Joanna Q Hudson, PharmD BCPS

Associate Professor, College of Pharmacy, University of Tennessee, Memphis

Reprints: Dr. Joy, University of North Carolina, School of Medicine, Division of Nephrology, Carolina Kidney Center, CB #7155, 7005 Burnett Womack Bldg., Chapel Hill, NC 27599-7155, fax 919/966-4251, Melanie_Joy{at}med.unc.edu

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of lanthanum carbonate, a phosphate binder for chronic kidney disease (CKD).

DATA SOURCES: Information was selected from PubMed (1965-October 2005). All studies presented as scientific posters and abstracts from nephrology meetings from 1999 to 2005 were also included.

STUDY SELECTION AND DATA EXTRACTION: All published articles regarding lanthanum carbonate were included. In addition, abstracts and presentations from scientific meeting symposia were also considered for inclusion.

DATA SYNTHESIS: Lanthanum carbonate has been recently approved as non-calcium-based therapy for phosphate reduction in patients with stage 5 CKD requiring dialysis. The recommended dose is 250-500 mg with meals, for a maximum of 1500 mg daily. Clinical studies have shown short- and long-term safety with lanthanum carbonate administration. Adverse effects were primarily gastrointestinal in nature. Clinical trials have also shown reductions in serum phosphorus to target concentrations, reductions in associated calcium-phosphorus product, and minimal effects on serum calcium and parathyroid hormone concentrations.

CONCLUSIONS: Lanthanum carbonate is an effective phosphate-binding agent without significant risk of hypercalcemia or worsening metabolic acidosis. Lanthanum carbonate is a safe and effective drug for reduction of elevated serum phosphorus levels associated with stage 5 CKD. The role of lanthanum carbonate relative to other phosphate-binding drugs, such as calcium salts and sevelamer, remains to be determined.

Key Words: chronic kidney failure, lanthanum carbonateA

Published Online, January 31, 2006. www.theannals.com, DOI 10.1345/aph.1G224




homecopy help contact us subscription past issues search current issue
Copyright © 2006 by Harvey Whitney Books Company.